comprehensive -WSS

comprehensive

author：explore 2025-10-01 17:21:42 - browse：668

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Abortion pill case raises question: who can sue the FDA?

knowledge

WSS

Washington mulls new rules to avert another Change Healthcare

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Readout Newsletter: Merck, Vertex, and Viking updates

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Decaf coffee targeted by food safety group under obscure FDA rule

Readout LOUD podcast: mifepristone case, GLP

leisure time

comprehensive

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Drug repurposing or repositioning? The language matters

Bernie Sanders gets little from pharma CEOs on drug prices

Medicare proposal to cover medical devices draws a mixed reaction

Oprah kicked off a national conversation on obesity. Let's have it

Novavax promises a turnaround & Lilly roils the obesity market

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Wildfire smoke exposes gaps in outdoor worker protections

AMAs digital advisors table RPM coding reform proposal, again

focus

AMAs digital advisors table RPM coding reform proposal, again

Abortion pill Supreme Court ruling could impact entire drug industry

Tome Biosciences co

Why the world’s most expensive drug might be worth the price

Congress might make insulin pumps more accessible to the blind

Congress considering partial increase for doctor pay in Medicare

knowledge

hotspot

focus

knowledge